Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
RedHill Biopharma Ltd (NASDAQ: RDHL) is a specialty biopharmaceutical leader focused on gastrointestinal and infectious disease therapies. This page provides investors and industry professionals with comprehensive updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including FDA submissions, clinical trial results, and partnership agreements. Track progress across RedHill’s commercial products like Talicia for H. pylori and Aemcolo for travelers’ diarrhea, along with late-stage candidates such as opaganib in oncology and inflammatory diseases.
Our curated news collection enables informed decision-making by consolidating material events including earnings reports, intellectual property updates, and research collaborations. Content spans therapeutic area breakthroughs, management commentary, and market expansion activities.
Bookmark this page for streamlined access to verified RedHill Biopharma updates. Check regularly for developments impacting the company’s position in gastrointestinal therapeutics and pandemic preparedness research.
RedHill Biopharma reported 2020 financial results with net revenues of approximately $64 million, marking a significant increase of $58 million from 2019, driven by Movantik and Talicia sales. Gross profit stood at $27.5 million. Despite strong growth, the company faced an operating loss of approximately $64 million and a net loss of about $76 million. The company's cash balance was solid at $100 million as of March 2021. RedHill is progressing in COVID-19 therapeutics with two Phase 2/3 studies for Opaganib and RHB-107, expecting to achieve commercial operational breakeven by the end of 2021.
RedHill Biopharma Ltd. (Nasdaq: RDHL) will report its fourth quarter and full year 2020 financial results on March 18, 2021, during a conference call at 8:30 a.m. EDT. Highlights will include the company's full-year financial performance and ongoing clinical studies, particularly for COVID-19 treatments opaganib and RHB-107, as well as a Phase 3 study for RHB-204 targeting pulmonary nontuberculous mycobacteria disease.
The webcast will be available live on the company's website.
RedHill Biopharma Ltd. (Nasdaq: RDHL) will report its fourth quarter and full year 2020 financial results on March 18, 2021, at 8:30 a.m. EDT.
The company will detail 2020 financial performance, commercial activities, and updates on ongoing clinical studies for COVID-19 treatments (opaganib and RHB-107) and a Phase 3 study of RHB-204 for pulmonary nontuberculous mycobacteria.
The webcast will be available live on the company’s website and for replay for 30 days.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announces its participation in several virtual conferences throughout March 2021. Key events include:
- Sachs Spring Life Sciences Week (March 8-11) featuring Guy Goldberg, Chief Business Officer.
- Barclays Global Healthcare Conference (March 9-11) with CEO Dror Ben-Asher on March 11.
- H.C. Wainwright Global Life Sciences Conference (March 9-10) also with Guy Goldberg.
- 33rd Annual Roth Conference (March 15-17), presentation by Guy Goldberg.
- BIO-Europe Spring Digital Conference (March 22-25) with Adi Frish.
Webcasts will be available on RedHill's website for 30 days.
RedHill Biopharma Ltd. (Nasdaq: RDHL) has completed a public offering of 4,375,000 American Depositary Shares (ADSs) at $8.00 each, raising gross proceeds of $35 million. The offering includes a 30-day option for the underwriter to purchase an additional 656,250 ADSs. The funds will support the company's clinical development, commercialization efforts, and general corporate purposes. H.C. Wainwright & Co. served as the book-running manager for the offering. This offering is part of a previously filed shelf registration with the SEC.
ObvioHealth has announced a hybrid clinical trial for COVID-19 treatment utilizing RedHill Biopharma's RHB-107 (upamostat). The Phase 2/3 study will monitor over 300 symptomatic COVID-19 patients remotely, assessing RHB-107's safety and efficacy. This innovative approach combines digital health technologies with home healthcare to enhance patient monitoring while minimizing hospital visits. RHB-107 is designed to combat emerging viral strains, offering a promising oral therapy option. The trial's unique setup fosters data collection while safeguarding participant health.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced an increase in its public offering to 4,375,000 American Depositary Shares (ADSs) at $8.00 per ADS, aiming for gross proceeds of $35 million. The offering, managed by H.C. Wainwright & Co., expects to close by March 4, 2021. RedHill will use the funds for clinical development, commercialization, acquisitions, and corporate purposes. An additional 656,250 ADSs may be purchased by the underwriter within 30 days. This offering follows a shelf registration statement effective since August 2019.
RedHill Biopharma (Nasdaq: RDHL) announced an increase in its public offering to 4,375,000 American Depositary Shares (ADSs) at $8.00 per ADS, aiming for gross proceeds of approximately $35 million. Closing is expected on March 4, 2021. The underwriter, H.C. Wainwright & Co., has an option for an additional 656,250 ADSs. Proceeds will support clinical development, commercialization, acquisitions, and general corporate purposes. The offering is being made under a 'shelf' registration statement effective since August 2019.
RedHill Biopharma Ltd (Nasdaq: RDHL) announced a firm commitment underwriting agreement with H.C. Wainwright & Co. for the sale of 1,250,000 American Depositary Shares (ADSs) at $8.00 each, with gross proceeds expected to reach $10 million. The closing is anticipated on or around March 4, 2021, subject to customary conditions. Additionally, there is a 30-day option for the underwriter to purchase up to 187,500 additional ADSs. Proceeds will be used for clinical development, commercialization, and general corporate purposes.
RedHill Biopharma (Nasdaq: RDHL) announced the expansion of its global Phase 2/3 study for opaganib, targeting severe COVID-19, to the U.S. The move follows FDA recommendations after reviewing Phase 2 data. The study, with 464 patients planned across 8 countries, is over 50% enrolled and expected to provide top-line data in Q2 2021. Preliminary results indicate opaganib significantly reduced oxygen requirements and demonstrated a robust safety profile in its Phase 2 study. Opaganib, a novel oral SK2 inhibitor, shows promise against viral variants and additional oncological applications.
FAQ
What is the current stock price of Redhill Biopharm (RDHL)?
What is the market cap of Redhill Biopharm (RDHL)?
